Tests diagnostiques rapides et au point d’intervention pour le SARS-COV-2 (COVID-19) – Résumé rapide des tests accessibles au Canada
Statut du projet: Terminé
Utilisateur(s) des connaissances
Ministère des Soins de longue durée de l’Ontario
Source(s) de financement
Instituts de recherche en santé du Canada (IRSC), dans le cadre de l’Alliance pour des données probantes de la Stratégie de recherche axée sur le patient (SRAP)
Objectif du projet
1) Recenser les tests diagnostiques au point d’intervention pour le SARS-COV-2 (COVID-19) accessibles au Canada; 2) déterminer dans quelle mesure les tests diagnostiques au point d’intervention autorisés au Canada permettent de dépister avec exactitude les personnes atteintes de la COVID-19; 3) recenser les recommandations et les lignes directrices existantes concernant l’utilisation des tests diagnostiques au point d’intervention pour dépister les personnes atteintes de la COVID-19; et 4) déterminer les principaux avantages et limites des tests diagnostiques au point d’intervention pour la COVID-19 autorisés au Canada.
Approche de recherche
Revue rapide
Responsables du projet
George Wells
University of Ottawa Heart Institute
Shannon Kelly
Shannon Kelly currently manages and works as a senior research methodologist in the Heath Technology Assessment Unit of the Cardiovascular Research Methods Centre (CRMC) at the University of Ottawa Heart Institute where she focusses her work on advancing the science of evidence synthesis, research design and methodology. Her team conducts evidence syntheses to inform health care practice and policy. In this capacity, she has worked with a number of organizations nationally and internationally, including the Canadian Agency for Drugs and Technologies in Health (CADTH), the Public Health Agency of Canada, the World Health Organization and the Cochrane Collaboration.
Shannon is currently a PhD candidate in the Faculty of Medicine, School of Epidemiology and Public Health at the University of Ottawa and a trainee with the Cardiovascular Network of Canada (CANet) National Centre of Excellence. In her capacity with CANet, she sits on the Board of Directors. Shannon has been actively involved with post-market Drug Safety and Effectiveness Network (DSEN) since 2011 and has led numerous research projects for the Ontario Drug Policy Research Network, the Canadian Collaboration for Network Meta-analysis (CCNMA), the Methods and Application Group for Indirect Comparisons (DSEN- MAGIC) and the POst-market Drug Evaluation Team (PODET). In addition, Shannon leading a working group to develop nutrition-specific risk of bias tools (NUQUEST).
Shannon Kelly
University of Ottawa Heart Institute
Shannon Kelly currently manages and works as a senior research…